Pld ovarian cancer
Webb7 aug. 2012 · This study was previously presented at the 2011 American Society of Clinical Oncology Annual Meeting: Marth C, Alexandre J, Hanker LC, et al. Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival … Webb13 apr. 2024 · The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma, who were …
Pld ovarian cancer
Did you know?
Webb23 mars 2024 · Adding trabectedin to PLD as third-line therapy significantly prolongs OS and PFS in BRCA1/2-mutated patients with advanced epithelial ovarian cancer. ... Study explores third-line trabectedin plus PLD for BRCA1/2 ovarian cancer. Publish date: … Webb19 okt. 2024 · Lurbinectedin (L) is a new anticancer agent that blocks transcriptional transactivation, induces DNA double-strand breaks, and modulates the tumor …
Webb7 feb. 2024 · Introduction Bevacizumab and gemcitabine are key drugs for treating recurrent epithelial ovarian cancer. However, information about the combination of bevacizumab and gemcitabine is insufficient. We conducted a phase II study to assess the feasibility, clinical activity, and toxicity of this combination chemotherapy. Methods This … Webb14 apr. 2024 · Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed precision oncology strategy has …
Webb19 okt. 2024 · L showed activity in platinum-resistant ovarian cancer (PROC) patients (pts) in a randomized phase II trial in comparison to topotecan (Ann Oncol 2024; 28:1280). Methods Pts with PROC [platinum-free interval [PFI] 1-6 months (mo) after last platinum chemotherapy (CT)] treated with ≤3 prior CT lines and ECOG PS 0-2 were eligible. Webb9 feb. 2024 · Ovarian carcinoma (OC) accounts for only 2.3% of all new cancer cases in females but it is the fifth leading cause of all cancer-related deaths [].Such a burden appears mainly due to the lack of ...
Webb9 mars 2024 · Background: Previous meta-analysis studies suggested that pegylated liposomal doxorubicin (PLD) may improve the survival rate of patients with recurrent …
Webb23 juni 2011 · Prior resistance to anthracyclines or PLD defined as a progression during anthracycline-based chemotherapy or a recurrence within 6 months from its ending Prior severe PLD related toxicity Prior exposure to cumulative doses of doxorubicin >400mg/m2 or epirubicin >720mg/m2 property 24 westlandsWebb25 juli 2008 · The objective of this study is to compare progression-free survival (PFS), based upon investigator assessment using Response Evaluation Criteria In Solid Tumors … property 24 westcliffWebb21 sep. 2016 · Purpose Ovarian cancer (OC) patients experiencing progressive disease (PD) within 6 months of platinum-based therapy in the primary setting are considered platinum resistant (Pt-R). Currently, pegylated liposomal doxorubicin (PLD) is a standard of care for treatment of recurrent Pt-R disease. On the basis of promising phase II results, … property 24 westmead pinetownWebb1 apr. 2024 · Here we characterize immunophenotypic changes associated with BRCA1 dysfunction in ovarian cancer cells, and evaluate the T cell contribution to the therapeutic efficacy of PLD in a BRCA1- ovarian ... property 24 westvilleWebb9 mars 2024 · The 2024 NCCN Guidelines included PLD as a first-line chemotherapy regimen for ovarian cancer, and a regimen of carbo combined with PLD is recommended … property 24 western cape oudtshoornWebb13 apr. 2024 · Ovarian cancer survival, high recurrence rates, and toxicity of current treatment regimens have led researchers to strive for improvements in first-line treatment. This review brings you up-to-date. property 24 westonariaWebbTrabectedin plus pegylated liposomal doxorubicin (PLD) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of prior use of antiangiogenics: First … property 24 western cape somerset west